Tramapar

Quick links to important sections

Tramapar

Treatment option: Pain

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tramapar

Quick Facts

Property Description
Active Ingredients Tramadol Hydrochloride and Acetaminophen (Paracetamol)
Form Oral Tablets (Fixed-Dose Combination)
Pharmacological Class Analgesic Combination (Central-acting Opioid and Non-Opioid)
General Purpose Pain Management via Multimodal Analgesia
Origin Synthetic (components and final preparation)

What is Tramapar and Its Pharmacological Identity?

Tramapar is formally defined as a Fixed-Dose Combination (FDC) Product classified within the Analgesic Combination class for general Pain Management. This oral medicinal product strategically integrates two distinct Active Pharmaceutical Ingredients (APIs): the Opioid Analgesic, Tramadol Hydrochloride, and the Non-Opioid Analgesic, Acetaminophen (Paracetamol). This dual-component approach is central to its therapeutic strategy, providing a method of pain relief characterized by the interaction of its two primary ingredients. The product is a Prescription-only Medication that leverages its specific dual composition to enhance the overall effect on pain management.

Composition: The Synergistic Combination of Active Ingredients

The unique identity of Tramapar stems from the synergism of its two synthetic components. Tramadol Hydrochloride and Acetaminophen are combined into a single Oral Tablet to allow for simultaneous action. The combination provides Multimodal Analgesia, meaning the components address pain through non-overlapping mechanisms. This specific combination is designed to deliver supra-additive pain reduction compared to either ingredient administered alone. This structural and pharmacological design ensures the preparation targets discomfort using multiple mechanisms concurrently.

What is the General Purpose of This Dual-Action Analgesic?

The fundamental purpose of this dual-action analgesic is to provide efficient Pain Management by leveraging the Central Nervous System (CNS) Action of both components. The core characteristic of this formulation is the improved nociception modulation resulting from the combined effect of the opioid and non-opioid elements. This preparation acts to reduce the intensity of pain perceived by the user, representing an integrated strategy for pain control designed for the Adult Patient.

What side effects are possible with Tramapar?

Possible Side Effects and Safety Information

The safety profile of this medicine is defined by adverse reactions categorized by frequency and the organ systems affected, as documented in regulatory sources like the FDA and SmPC. Adverse effects primarily occur in the Nervous System and the Gastrointestinal System.


Frequency-Classified Adverse Reactions

Official regulatory documents classify the occurrence of adverse reactions:

  • Very Common (occurring in ge 1/10 patients): Nausea, Dizziness, and Somnolence (drowsiness).
  • Common (occurring in ge 1/100 to < 1/10 patients): Vomiting, Constipation, Dry mouth, Headache, Confusion, and Increased Sweating.

Other less frequent reactions (Uncommon and Rare) may affect systems including the Hepatobiliary (liver), Cardiac, and Renal systems.


Serious Adverse Reactions and Key Constraints

The official labeling highlights several serious adverse reactions, which, while rare, are clinically significant. These include the risk of Life-Threatening Respiratory Depression, the potential for Seizures, and the risk of Hepatotoxicity (liver damage), particularly if the recommended maximum dose is exceeded. The risk of Serotonin Syndrome is also documented, especially with concomitant use of certain other medicines.

Safety notes specify that effects like nausea and dizziness may be more prominent during the initial treatment phase. Furthermore, risks such as physical dependence and tolerance are associated with long-term exposure.

  • Safety Constraints: The medicine is contraindicated in conditions such as severe hepatic insufficiency, significant respiratory depression, and in children younger than 12 years of age, based on regulatory determinations. The official safety documentation also requires close monitoring for elderly patients and those with renal or hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Tramapar overdose is defined by the dual toxic potential of its components, requiring immediate professional response. Overdose manifestations stemming from the tramadol component include Central Nervous System (CNS) depression, miosis (pinpoint pupils), convulsions/seizures, and progressive consciousness disorders up to coma.

Life-Threatening Outcomes

A primary, life-threatening risk is respiratory depression, which can lead to respiratory arrest and cardiovascular collapse. Toxicity from the acetaminophen component introduces the critical risk of acute liver failure, which may progress to hepatic encephalopathy and be fatal. Regulator-documented severe outcomes also include acute renal failure and the potential for Serotonin Syndrome.

Regulator-Mandated Emergency Actions

Immediate medical attention is mandated for any suspected overdose. Official regulatory guidance requires the patient to contact the nearest poison centre or hospital immediately, even if initial symptoms are mild or absent. Specific interventions are documented, including the use of Naloxone for opioid-related respiratory depression and the administration of N-acetyl Cysteine (NAC) as the antidote for acetaminophen toxicity. Hospital monitoring, including repeated hepatic tests and blood concentration measurements, is required for comprehensive management. Accidental ingestion, especially by young children, carries a specific risk of fatal overdose.

Therapeutic Uses of Tramapar

What Tramapar treats: main uses and benefits

Tramapar is applied across domains where additional symptomatic support is needed, generally for managing symptoms related to physical discomfort of moderate to moderately severe intensity. This combination analgesic is applied when standard, non-opioid treatments do not adequately ease symptoms, relevant in contexts marked by increased discomfort or tension. It is commonly used across conditions presenting with acute episodes, such as managing discomfort during phases following operative procedures, acute musculoskeletal injuries, and the sudden intensification of symptoms associated with chronic conditions like osteoarthritis flares.

The combination may assist with providing symptomatic relief that supports patients during episodes of heightened discomfort. By assisting with maintaining functional stability and addressing symptoms that interfere with daily comfort, Tramapar contributes to easing the overall symptom burden.


Quick Fact: Relief for Moderate Pain
Target Symptom Severity Moderate to moderately severe pain
Typical Contexts Post-procedural pain, acute injury, chronic flare-ups
Primary Benefit Supportive symptomatic control and functional stability assistance

Eligibility and Restrictions for Use

The official regulatory profile for Tramapar (Tramadol and Acetaminophen) strictly defines eligibility based on age, organ function, and concurrent clinical status.


Eligibility scope

Classification Population Rule Status
Approved Age Adults and Adolescents (Aged 12 years and older) Allowed
Absolute Ban Children younger than 12 years of age Contraindicated
Absolute Ban Patients with severe hepatic impairment (liver disease) Contraindicated
Absolute Ban Use with MAO inhibitors (or within 14 days of stopping) Contraindicated
Absolute Ban Patients with uncontrolled epilepsy or severe respiratory depression Contraindicated

Condition-Specific Limitations

Condition/Status Regulatory Statement
Renal Impairment Use is not recommended in patients with severe kidney problems (creatinine clearance <30 mL/min).
Pregnancy Not recommended; prolonged use can result in Neonatal Opioid Withdrawal Syndrome in the newborn.
Lactation Not recommended; tramadol and its metabolites are excreted into breast milk.
Older Adults (ge 75 years) Requires special caution; the dosing interval may need to be extended due to prolonged drug elimination.

Connection to the overall eligibility profile

Regulatory documents establish a strict framework for this combination medicine by formally contraindicating its use in specific populations. These exclusions are primarily tied to age, severe organ dysfunction, and conditions that present a high risk of life-threatening respiratory depression or hepatotoxicity, ensuring the profile remains focused exclusively on eligibility and non-eligibility.

What should I know about interactions with other medicines?

This combination medication contains tramadol and acetaminophen. Do not take this product if you are currently using any other medicine that contains acetaminophen or tramadol, as this increases the risk of serious side effects, including liver damage or overdose.

Major Interaction Risks

  • Monoamine Oxidase Inhibitors (MAOIs): Use with MAOIs (or within 14 days of stopping them) is contraindicated due to the serious, potentially fatal risk of Serotonin Syndrome and seizures. Serotonin Syndrome is characterized by symptoms like agitation, confusion, fever, rapid heart rate, and severe muscle stiffness.
  • CNS Depressants and Alcohol: Concomitant use with alcohol, benzodiazepines, other opioids, tranquilizers, or sleeping pills significantly increases the risk of profound sedation, respiratory depression, coma, and death.
  • Serotonergic Drugs and Others that Lower the Seizure Threshold: Taking Tramapar with other serotonergic medicines (such as SSRIs, SNRIs, or triptans) or drugs that lower the seizure threshold (e.g., certain tricyclic compounds, neuroleptics, or bupropion) can increase the risk of seizures or Serotonin Syndrome.

Other Notable Interactions

  • Enzyme Inhibitors/Inducers: Medicines that affect the liver enzymes CYP2D6 (e.g., quinidine, fluoxetine) or CYP3A4 (e.g., ketoconazole, carbamazepine) can alter the amount of tramadol or its active metabolite (M1) in the body, potentially reducing pain relief or increasing the risk of adverse effects like seizures.
  • Blood Thinners: Use with warfarin or similar anticoagulants requires close monitoring, as Tramapar may alter the blood-thinning effect, increasing the risk of bleeding.

Mechanism of Action

Tramapar acts through a unique dual mechanism, engaging two distinct physiological systems to influence the transmission of signals within the central nervous system.


Opioid Receptor Modulation

This domain involves the action of the drug and its active metabolite (O-desmethyltramadol) as a weak agonist on mu-opioid receptors in the central nervous system. The resulting receptor-ligand interaction modulates descending inhibitory pathways.


Monoamine Neurotransmitter Reuptake Inhibition

Tramapar also modulates key pathways by weakly inhibiting the reuptake of two important neurotransmitters: serotonin and norepinephrine. This action increases the concentration of monoamines in the synaptic cleft, influencing the function of descending monoaminergic pathways.

Dosage and Administration Information

Administration and Dosing Principles

Tramapar is administered by the oral route only, as a fixed-dose combination tablet. Each tablet contains 37.5 mg of tramadol hydrochloride and 325 mg of acetaminophen. The tablets must be swallowed whole with liquid and should not be broken, crushed, or chewed. The medicine can be taken with or without food. Patients are instructed to avoid using any other medications that contain tramadol or acetaminophen concurrently.


Standardized Regimens and Timing

The typical initial and maximum single dose for adults is two tablets. The maximum total dose administered in a 24-hour period must not exceed eight tablets. The product is taken on an as-needed (PRN) basis, with a minimum interval of six hours required between any two doses to prevent ingredient accumulation. Treatment duration should generally be limited and should generally not exceed five days.


Population-Specific Use Constraints

For patients with severe renal impairment (creatinine clearance less than 30 mL/min), the dosing frequency must be reduced, typically not exceeding two tablets every 12 hours. Use in cases of severe hepatic impairment is not recommended. For older adults (those aged 75 years and above), the minimum interval between doses is six hours, ensuring that the dosing schedule is extended.

Recent Clinical Evidence

Research evidence / Overview of studies

Clinical Efficacy Studies

Clinical trials have focused on examining the compound's potential application in chronic osteoarthritis.

  • Joint Function: Studies examined whether the combination of the two active ingredients could influence measures of joint mobility and joint stiffness. These evaluations typically used standardized patient-reported outcome measures and physical examinations.
  • Pain Management: Results from various trials indicate changes in pain scores were evaluated, often within a 48-hour window. These assessments used visual analog scales (VAS) and other validated pain instruments.
  • Swelling Reduction: Studies examined the compound's influence on measures of swelling, generally through circumference measurements of affected joints.

Safety and Tolerability Profile

The profile of the compound was evaluated through several Phase II and Phase III studies.

  • Long-term Profile: Long-term studies over five years explored the relationship between the compound and the progression of the disease.

Comparative Research

One Phase III trial compared outcomes between the compound and a non-steroidal anti-inflammatory drug (NSAID) comparator. This study focused on assessing changes in key endpoints such as average daily pain and the incidence of gastrointestinal side effects between the two groups over a six-week period.

Key Studies & References American College of Rheumatology (ACR) Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee

Frequently Asked Questions (FAQ)

Common questions about Tramapar (FAQ)

Q: Is Tramapar the same kind of medicine as Advil or Tylenol?

No. Official documents describe Tramapar as a Fixed-Dose Combination product. It contains two active ingredients: the synthetic opioid analgesic, tramadol, and the non-opioid analgesic, acetaminophen. This dual-action mechanism is distinct from single-ingredient medicines like acetaminophen alone (Tylenol) or non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen (Advil).


Q: Is Tramapar considered a narcotic or controlled substance?

Yes, the tramadol component of the medication is regulated by the U.S. federal government. It is classified as a Schedule IV controlled substance due to its potential for misuse, abuse, and dependence.


Q: What are the signs of a serious reaction to Tramapar?

Regulatory information indicates that serious reactions can include signs of Liver Damage (symptoms like yellowing of the skin or eyes, dark urine), Respiratory Depression (slow, shallow, or troubled breathing), and Serotonin Syndrome (symptoms like agitation, confusion, or an increased heart rate).


Q: Do I need to avoid any specific foods or drinks while using Tramapar?

Official labeling explicitly warns against the use of alcohol and other Central Nervous System (CNS) depressants due to the risk of life-threatening respiratory depression. No specific foods are prohibited, but official information notes that a high-fat meal can affect how quickly the drug is absorbed.


Q: What is the difference between Tramapar and other similar medicines?

Tramapar is structurally defined as an analgesic combination that provides multimodal analgesia. It differs from many single-ingredient pain medicines by combining two analgesic classes—an opioid and a non-opioid—into one tablet to target pain through multiple mechanisms simultaneously.


Q: Are there any warnings about using Tramapar before driving?

Official patient safety information contains a warning against driving or operating heavy machinery. This is because the medication can cause dizziness, sleepiness, or lightheadedness.


Q: Why does the packaging for Tramapar have a special warning?

The packaging features the most stringent warning required by the FDA, known as a Boxed Warning. This is used to draw attention to the most significant safety risks, which include the potential for Addiction, Abuse, and Misuse, the risk of Life-Threatening Respiratory Depression, and the risk of Hepatotoxicity (liver damage) from the acetaminophen component.


Q: Is it okay to stop taking Tramapar suddenly?

Official labeling warns against the abrupt discontinuation of the drug, especially after extended use. Rapidly stopping opioid analgesics can lead to serious withdrawal symptoms and uncontrolled pain. Official documentation mentions that a gradual reduction in dosage is generally discussed for the process of discontinuation.


Q: How quickly does Tramapar start to work?

Pharmacokinetic data indicates that the drug generally begins to provide pain relief within one hour after it is administered. However, regulatory documents mention that consuming the medicine with a high-fat meal may extend the time it takes to reach its maximum concentration.


Q: How long does the effect of Tramapar last?

The analgesic effects typically last around six hours.


Q: Can Tramapar affect blood pressure?

Yes, official regulatory documents list both an increase in blood pressure (Hypertension) and a decrease in blood pressure (Hypotension) as potential adverse effects that have been reported.


Q: Do any herbal supplements or vitamins interact with Tramapar?

Official patient guides state that a healthcare provider should be informed of all herbal supplements, vitamins, and over-the-counter medicines being used. This is necessary because concurrent use of certain products may carry risks of serious side effects.


Q: What should I do if I miss a dose of Tramapar?

Regulatory guidance addresses the question of a missed dose by stating that the dose should be skipped and the next dose taken at its regularly scheduled time. The guidance also advises against taking double or extra doses to compensate for a missed amount.


Q: Do patients commonly report weight changes while using Tramapar?

Regulatory documents list a decrease in weight (Weight decrease) as a side effect that was reported in clinical trials. However, this effect was recorded in less than 1% of the total patients studied.


Q: Is 'Tramapar' the brand name or generic name?

Tramapar is a reference name for the drug's generic combination: tramadol hydrochloride and acetaminophen. This specific fixed-dose combination is manufactured and sold by pharmaceutical companies under various brand names.

How should Tramapar be stored and disposed of?

How to Store and Dispose of Tramapar?

Tramapar (Tramadol/Acetaminophen) must be stored and handled according to regulatory requirements to maintain product stability and ensure public safety, particularly due to its opioid component.


Storage Requirements

The medicine must be stored at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F), and must be kept below 30 C. It is mandatory to keep from freezing and to protect the tablets from light and moisture. The product must be kept in a tight container, often the original packaging, and stored securely out of the sight and reach of children.


Disposal Instructions

Unused or expired Tramapar should be discarded safely via an authorized drug take-back program. If a take-back option is not available, official guidance specifies that the medicine should be immediately flushed down the toilet to prevent accidental ingestion or misuse.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tramapar found in:

A-Z Index: